Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2024 08:30 ET | Source: AnaptysBio, Inc.

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in...
November 05, 2024 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Top-line Phase 2b data anticipated for ANB032, our BTLA agonist, in atopic dermatitis (AD) in December 2024Top-line Phase 2b data anticipated for rosnilimab, our PD-1 agonist, in rheumatoid arthritis...
November 05, 2024 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Participation in November and December Investor Conferences

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
August 29, 2024 09:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that...
August 14, 2024 05:00 ET | Source: AnaptysBio, Inc.

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the...
August 05, 2024 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Top-line data expected in December 2024 after having completed enrollment for Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonistTop-line data accelerated and now anticipated...
May 09, 2024 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist; reiterating top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b...
May 09, 2024 16:10 ET | Source: AnaptysBio, Inc.

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in...
May 09, 2024 16:05 ET | Source: AnaptysBio, Inc.

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Anaptys to receive $50 million upfront cash payment from Sagard HealthcarePrior agreement amended to now expire once Sagard receives a capped payoff of either $600 million if received by March 31,...
March 11, 2024 16:15 ET | Source: AnaptysBio, Inc.

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Enrollment ongoing for global Phase 2b trial to treat atopic dermatitis (AD) with ANB032, our BTLA agonist, with top-line data anticipated by year-end 2024Enrollment ongoing for global Phase 2b trial...